Comparative Pharmacology
Head-to-head clinical analysis: PYRIMETHAMINE SULFADOXINE versus SOVUNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYRIMETHAMINE SULFADOXINE versus SOVUNA.
Pyrimethamine-Sulfadoxine vs SOVUNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyrimethamine inhibits dihydrofolate reductase, blocking tetrahydrofolate synthesis. Sulfadoxine inhibits dihydropteroate synthase, blocking folate synthesis. Sequential blockade of folate metabolism.
SOVUNA (suvorexant) is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides to orexin OX1 and OX2 receptors, thereby promoting sleep initiation and maintenance.
Pyrimethamine 25 mg plus sulfadoxine 500 mg per tablet; typical adult dose for acute uncomplicated malaria is 3 tablets (pyrimethamine 75 mg, sulfadoxine 1500 mg) orally as a single dose. For toxoplasmosis in immunocompromised patients: loading dose pyrimethamine 200 mg orally once, then pyrimethamine 50-75 mg orally once daily plus sulfadoxine 1000-1500 mg orally once daily (dosing based on sulfadoxine component) for 4-6 weeks, then reduce to half.
400 mg orally once daily with food.
None Documented
None Documented
Pyrimethamine: ~80-120 hours; Sulfadoxine: ~100-200 hours. Long half-lives allow single-dose therapy for malaria.
Terminal half-life 14 hours; clinically significant for once-daily dosing, requiring dose adjustment in renal impairment (CrCl <30 mL/min).
Renal: ~60% unchanged sulfadoxine, ~5% unchanged pyrimethamine; fecal: ~10% pyrimethamine. Biliary excretion minimal.
Primarily renal (70% unchanged) and 20% fecal via bile; minor metabolic clearance.
Category C
Category C
Antimalarial
Antimalarial